The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.

Timothy A  Yap

Honoraria - AstraZeneca; Pfizer

Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex

Speakers' Bureau - AstraZeneca

Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex

Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)

Travel, Accommodations, Expenses - EMD Serono; Pfizer; Tesaro

Kyriakos P.  Papadopoulos

Consulting or Advisory Role - ArQule (Inst); Bayer (Inst)

Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)

Patricia  LoRusso

Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; Chiltern; CytomX Therapeutics; Five Prime Therapeutics; Genentech; Genmab; Glenmark; Halozyme; Ignyta; Menarini; Novartis; Novella Clinical; Omniox; Roche/Genentech; Takeda

Research Funding - Alexion Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)

Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche

Deborah J.L.  Wong

Honoraria - Bristol-Myers Squibb

Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche

Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Bristol-Myers Squibb; Genentech/Roche; Kura Oncology; Merck Serono; Merck Sharp & Dohme; Regeneron

Siwen  Hu-Lieskovan

Consulting or Advisory Role - Amgen; Genmab; Merck

Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Nektar (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Vaccinex (Inst)

Josefin-Beate  Holz

Stock and Other Ownership Interests  - Biogen; Gilead Sciences

Consulting or Advisory Role - F-Star Biotechnology

Travel, Accommodations, Expenses - F-Star Biotechnology